Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASH 2020 | Updates in transplantation at ASH 2020

Name: Updates in transplantation at ASH 2020
Uploaded: 2021-01-15T00:00:00Z
Duration: 1 min 26 s
Description: Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA, discusses the most recent developments and emerging novel therapies for graft versus host disease (GvHD) including updates from the REACH3 trial (NCT03112603) of ruxolitinib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Corey Cutler • 15 Jan 2021

ASH 2020

Ruxolitinib

REACH3

Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA, discusses the most recent developments and emerging novel therapies for graft versus host disease (GvHD) including updates from the REACH3 trial (NCT03112603) of ruxolitinib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

1:40

The ROCKstar study: belumosudil for chronic GvHD

Corey Cutler • 15 Jan 2021

1:26

RIC allogeneic HCT for high-risk MDS

Corey Cutler • 15 Jan 2021

ASH 2020 | Updates in transplantation at ASH 2020

More from Corey Cutler

Cookie settings